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Abstract
The technology of gene targeting through homologous recombination has been extremely useful
for elucidating gene functions in mice. The application of this technology was thought impossible in
the large livestock species until the successful creation of the first mammalian clone "Dolly" the
sheep. The combination of the technologies for gene targeting of somatic cells with those of animal
cloning made it possible to introduce specific genetic mutations into domestic animals. In this
review, the principles of gene targeting in somatic cells and the challenges of nuclear transfer using
gene-targeted cells are discussed. The relevance of gene targeting in domestic animals for
applications in bio-medicine and agriculture are also examined.
Introduction
Discovery of the functions of genes is a remarkably impor-
tant aspect of biological research. Precise genetic modifi-
cations of animals are a powerful methodology to study
physiological mechanisms at the molecular level. Gene
knock-in and knock-out through gene targeting mediated
by DNA homologous recombination paved the way
towards the era of mammalian functional genomics. Fol-
lowing the first report of mouse embryonic stem (ES) cells
in 1981 [1,2] and the successful alteration of the hypoxan-
thine phosphoribosyl transferase (HPRT) gene locus
through homologous recombination in mouse ES cells in
1989 [3,4], numerous mouse mutants generated through
gene targeting have been reported. By the year 2000, an
estimated 5000 genes had been inactivated in the mouse
[5]. It has become routine in many laboratories around
the world to produce mice with specific genetic modifica-
tions including gene disruption, gene replacement, and
even engineered chromosomal translocation. However, it
has been extremely difficult to alter genes in mammals,
other than the mouse, by homologous recombination.
Although several ES cell lines have been established, pri-
marily from the 129/SvJ mouse strain, and are now com-
mercially available, cloning of ES cells from other
mammalian species has made only limited progress.
Embryo-derived pluripotent cell lines have been reported
in pigs [6] and cattle [7], but successful germ-line chimeric
offspring have not yet been reported. The failure to devel-
opment of ES cell lines has hampered many applications
of gene targeting technologies in domestic animals.
The breakthrough in animal cloning using somatic cells
[8] implies that targeted genetic manipulations of domes-
tic animals could be achieved by combining gene target-
ing in somatic cells and cloning. In this review, the
strategy and potential challenges of gene targeting manip-
ulation in the domestic animal are discussed. Some of the
applications of gene targeting in domestic animals for
bio-medicine and agriculture are also addressed.
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Gene targeting is the terminology used for genetic manip-
ulations of animal genomes using homologous recombi-
nation for the altering of gene activity in any purposeful
manner. Homologous recombination is the exchange of
homologous segments of two DNA molecules anywhere
along their length. The technology of homologous recom-
bination allows the precise modification (replacement or
deletion) of certain alleles in the genome. In mammals,
homologous recombination naturally occurs during the
meiosis cleavage of gamete cells. Two homologous chro-
mosomes undergo a crossing-over process at recombinant
hot areas, resulting in the exchange of chromosomal frag-
ments. A primary step in homologous recombination is
DNA exchange, which involves pairing of a DNA duplex
with at least one DNA strand containing a complementary
sequence to form an intermediate recombinant structure.
When two complementary DNA strands pair with a DNA
duplex, a classical Holliday recombination-joint may
form [9]. Once formed, a hetero-duplex structure may be
resolved by strand breakage and exchange, so that all or a
portion of an invading DNA strand is spliced into a recip-
ient DNA duplex, adding or replacing a segment of the
recipient DNA.
The majority of foreign DNA integration events in yeast
are homologous recombination [10] as opposed to ran-
dom illegitimate recombination in mammalian cells [11].
The research on DNA transformation in the 1970s in yeast
led to the development of the basic principles of gene dis-
ruption via homologous recombination in mammalian
cells. The insertion of DNA sequences into a human chro-
mosome by homologous recombination was first demon-
strated in 1985 by Smithies et al. [12] for the human β-
globulin locus. Later, Capacchi's work in 1989 [13] laid
the foundation for the development of the strategies of
gene targeting using mouse ES cells.
The most commonly used targeting vector in mouse ES
cells is the replacement vector (Fig. 1), which contains a
positive selection marker for selection of transformed
cells. Additionally, a negative selection marker is added
outside of the region of the homology to counter-select
the random integration following positive selection. Dur-
ing homologous recombination, the negative selectable
gene is lost because it is located at the distal region of
homology between a vector and a target. Therefore, the
cells containing negative selection markers are resulted
from random DNA integrations. Usually, the simplex
virus-thymidine kinase (HSV-tk) gene is used for negative
selection. The cells with the HSV-tk gene are sensitive to
the nucleotide analogs gancyclovir or 1-(2-deoxy-2-
fluoro-beta-D-arabino-furanosyl)-5-iodouracil (FIAU). As
a result, only the cells transformed through homologous
recombination are isolated following negative selection
[13]. This procedure is termed positive-negative selection
(PNS). The ES cells with targeted mutant genes can then
be injected into host blastocysts to derive chimeric mice.
Eventually, some of the chimeric mice could transmit the
genotype of the ES cells to their progeny.
The replacement vector for gene targetingFigu e 1
The replacement vector for gene targeting. The third exon of a target gene is disrupted by neomycin resistance marker 









locusPage 2 of 8
(page number not for citation purposes)
Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/103Gene targeting in somatic cells and animal 
cloning
The general strategy of gene targeting using animal cloning
The first animal cloned via nuclear transfer of an adult
somatic cell, Dolly the sheep [8], sparked vast interest in
nuclear reprogramming of somatic cells and animal clon-
ing. Nuclear transfer technology is now widely used by
numerous laboratories to produce animals from the
somatic cells of animal fetuses and adults. In the last sev-
eral years, the procedures of nuclear transfer have been
successfully applied to various mammalian species and
have resulted in live births of mice [14], cattle [15], goats
[16,17], pigs [18], rabbits [19] and cats [20]. Furthermore,
transgenic animals have been produced by cloning gene-
transfected fetal somatic donor cells in sheep [21], cattle
[22] and goats [17]. A procedure for producing cloned
animals through nuclear transfer of gene-targeted somatic
cells is shown in Fig. 2. Somatic cells (usually fetal fibrob-
lastic cells) are transfected in vitro by liposomes or electro-
poration, screened for gene targeting, and transferred into
enucleated oocytes. The couplets are electrically pulsed to
induce fusion and then activated for further development
in vitro. The embryos derived from nuclear transfer are
transferred into recipients which give birth to offspring
carrying mutations from the gene-targeted somatic cells.
Since cloning of pluripotent ES cells in domestic animals
has not been fully demonstrated, to date, it has not been
possible to knock-in or knock-out genes in domestic ani-
mals by the homologous recombination in ES cells and
the production of animal chimeras. Alternatively, the
technology of animal cloning might provide a basis for
gene targeting in farm animals. In fact, gene-targeted ani-
mal clones have been successfully produced in sheep [23]
and pigs [24] by homologous recombination in fetal
fibroblast cells and nuclear transfer.
Gene targeting in somatic cells
A number of parameters have been shown to influence
the frequency of homologous recombination in mouse ES
cells: (1) the frequency increases when longer homolo-
gous sequences are included in the targeting constructs
[25]; (2) homologous recombination with isogenic DNA
sequences is more efficient than with non-isogenic
sequences [26]; (3) absolute frequency of homologous
recombination appears to be locus dependant [27]. The
absolute targeting frequency in mouse ES cells varies from
1 × 10-5 to 1 × 10-6 per electroporated cell [28]. However,
accumulated evidence shows that gene targeting in
somatic cells is more difficult than in mouse ES cells, and
the frequency in somatic cells is about two orders of mag-
nitude lower than in mouse ES cells [29], for example,
ranging from 2.8 × 10-7 to 27.5 × 10-7 per cell in sheep
[30]. Apparently, mouse ES cells possess higher recombi-
nogenicity than somatic cells. Therefore, a more efficient
strategy for promoting homologous recombination is
required for gene targeting in somatic cells.
Although PNS for mouse ES cells can yield an enrichment
of about 2000 fold [13], PNS in somatic cells can only
achieve a 2–3 fold enrichment [12]. A powerful promot-
erless selection has been employed for increasing enrich-
ment of gene targeting events in somatic cells. In a
promoterless vector, the gene of the positive selection
marker lacks a promoter, it can only be expressed from the
internal promoter of the target gene following homolo-
gous recombination. In some very rare cases, non-homol-
ogous recombination events could still be recovered if the
targeting vectors integrate into the sites of chromosomes
close to an active promoter. Hanson et al. [12] reported
that an enrichment ratio of 5,000- to 10,000-fold with a
promoterless vector in a rat fibroblastic cell line for the c-
myc gene had been achieved. In a report of generating α
(1,3) galactosyltransferase knock-out porcine fetal
fibroblasts, it was also demonstrated that the promoter-
less targeting vector provided a significant enhancement
in gene targeting efficiency by eliminating a larger propor-
tion of random integration events in comparison to the
PNS strategy [31].
Procedure of producing gene-targeted animals (goats) by cloningFigure 2
Procedure of producing gene-targeted animals (goats) by 
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nuclear transfer must have high potency for population
expansion and a high stability of cytogenetic normalcy.
Theoretically, a total of ~45 population doublings are
required to generate gene-targeted cells for nuclear trans-
fer [32]. An obvious choice among the somatic cell types
is the fetal fibroblast cell due to its proved ability to pro-
duce cloned animals and the ease of population expan-
sion. The life span of the fetal fibroblast is about 30–50
population doublings in pigs and cattle [33] and 40–120
population doublings in sheep [30]. Therefore, it is possi-
ble to carry out gene targeting procedures with these cells.
Furthermore, it is feasible to introduce targeted mutations
into animals through nuclear transfer, since evidence
shows that populations of bovine fibroblasts, after more
than 45 cell doublings [34], or even in senescence [35],
retained their totipotency for supporting full develop-
ment of cloned embryos. Up to now, several reports of
gene-targeted modifications in sheep [23,36] and pigs
[24,37] using promoterless targeting vectors and fetal
fibroblastic cell lines have been published.
When somatic cells nearing senescence are used, chromo-
somal abnormality is the critical factor related to poor effi-
ciency of animal cloning. In sheep, telomeres degrade at a
rate of ~0.59 kb per year in vivo, but much faster in culture
[38]. When telomeres fall below a critical length, chromo-
somal abnormalities occur more frequently. Somatic cells
can be induced to prolong their longevity and retain
cytogenetic normalcy after a large number of population
doublings. Previous reports indicate that human diploid
fibroblasts can be immortalized by transfection with the
telomerase catalytic component. With this treatment, the
human fibroblasts could be cultured beyond 300 passages
without phenotypic or chromosomal abnormalities [39-
41]. Therefore, the expression of telomerase in targeted
somatic cells could be an effective treatment for improv-
ing the efficiency of animal cloning.
Applications of gene targeting in domestic 
animals
Xenotransplantation
Organ transplantation is the only known treatment for
many diseases involving terminal organ failure. Unfortu-
nately, the lack of availability of human organs has greatly
limited the number of patients who can receive this life-
saving treatment. Because of the serious shortage of
human organs, tremendous effort has been made world-
wide to the study for the use of genetically engineered ani-
mal organs as replacement organs for human
transplantation (Xenotransplantation).
Pigs are considered to be the most suitable animal for sup-
plying organs because their organs are physiologically and
anatomically compatible with those of humans [42], and
they are already a production animal slaughtered for food.
Furthermore, pigs can be easily bred, they are very prolific,
and can be housed in pathogen-free facilities to prevent
the transmission of infectious diseases [43]. One of the
major constrains to using pig organs for xenotransplasnta-
tion is complement-dependant hyper-acute rejection
(HAR), which occurs within a few minutes following tis-
sue transplantation between discordant species of ani-
mals. Hyper-acute rejection results in lyses of the
endothelial cells in the vessels of the transplanted organs
and ultimately in graft failure [43]. Human and old world
monkeys have natural antibodies against α (1, 3)-galacto-
syl epitopes on pig cells. Therefore, the best way to cir-
cumvent HAR is to knock-out the function of the α-1, 3-
galactosyltransferase gene in the pigs. Mice with an α-1, 3-
galactosyltransferase gene inactivated through homolo-
gous recombination are viable, and when human serum
bound to cells and tissues of these mice they showed sub-
stantially less xeno-antibody production than normal
mice [44]. One allele of the α-1, 3-galactosyltransferase
locus in the pig was successfully knocked out through
homologous recombination in somatic cells and subse-
quent nuclear transfer [24,37,45]. More recently, the sec-
ond allele of α-1, 3-galactosyltransferase gene has also
been inactivated by selection of a point mutation at the
second base of exon 9, which resulted in inactivation of
the gene. Four healthy piglets with double knock-out of α-
1, 3-galactosyltransferase gene were produced by nuclear
transfer [46]. Further analysis of the tissues and organs
from these double knock-out pigs in nonhuman primate
models will provide crucial information regarding the
mechanisms of HAR.
Knock-out of Prnp gene
Prion diseases have had a devastating impact on the pro-
duction of livestock, bovine spongiform encephalopathy
(BSE, one type of prion disease in bovine) is expected to
cause about $50 billion loss in UK. Now, it has been ascer-
tained that one variant of deadly Creuzfeldt Jacob disease
(CJD) in humans can be caused by consumption of ani-
mal products contaminated with the BSE pathogen [47].
Control of the BSE epidemic has become top priority
worldwide.
Animal prion diseases include scrapie of sheep and goats,
transmissible mink encephalopathy, chronic wasting dis-
ease of mule deer and elk, feline spongiform encephalop-
athy and BSE. The characteristics of these diseases are
infectious and vacuolar degeneration of the gray matter
neuropil. It was discovered by Prusiner in 1982 [48] that
the infectious agent was a protease-resistant protein,
which was termed a prion (PrP). A prion has a molecular
weight of 27–30 kDa and is encoded by a single copy
gene, Prnp in mammals. Prions exist in two major iso-
forms: the nonpathogenic or cellular form, designatedPage 4 of 8
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nated PrPSc. Prion diseases are caused by conversion of
PrPC to PrPSc through infection or genetic mutation. Once
a cell contains PrPSc, it appears to act as a conformational
template by which PrPC is converted to a new molecule of
PrPSc through protein-protein interactions [49].
Some evidence shows that normal prions play a role in
synaptic function [50] and copper binding [51]. However,
no developmental or behavioral abnormalities were
found in prion knock-out mice. Furthermore, in the prion
knock-out mice, homozygous null mice (Prnp0/0) fail to
develop the characteristic clinical and neuropathological
symptoms of scrapie after inoculation with mouse prions,
and they do not propagate prion infectivity [52,53].
Therefore, it is expected that removal of the Prnp gene
from cattle and sheep will result in these animals being
resistant to BSE and scrapie. Fetal fibroblast cell lines with
the deletion of one allele of the PrP gene have been estab-
lished in sheep by homologous recombination [30]. Four
cloned lambs were produced from nuclear transfer of the
PrP +/- somatic cells [36]. More investigations are needed
to evaluate the survivability of PrP0/0 domestic animals
and their resistance to prion diseases.
Inactivation of animal Ig genes
Human antibodies have numerous diagnostic and thera-
peutic applications. Current antibody production plat-
forms used in industry are not expected to meet future
demand for production capacity. Some of the strategies
for mass production of human antibodies involve: (1)
introducing the human immunoglobulin gene into mice
or large domestic animals (e.g. cattle) with their endog-
enous immunoglobulin gene inactivated, (2) producing
human monoclonal antibodies from mouse hybridoma
or polyclonal antibodies from large animal blood immu-
nized against the human antigen. To inactivate the endog-
enous immunoglobulin gene, gene disruption by
homologous recombination in mouse ES cells, or somatic
cells of large domestic animals, must be carried out in
order to introduce the mutation into the animals through
cloning.
Each antibody molecule consists of two classes of
polypeptide chains, light (L) chains (κ L-chain or λ L-
chain) and heavy (H) chains. A single antibody molecule
has two identical copies of the L chain and two of the H
chain. The loci of antibodies are very large and located on
different chromosomes (chromosome 14 (H-chain
locus), 22 (λ L-chain locus) and 2 (κ L-chain) in humans).
In their germ line configuration, these loci consist of
diverse segments encoding the variable (V), diversity (D)
and joining (J) genes that comprise the variable domains
along with the segments that encode the constant (C)
domains [54].
Mouse antibody is immunogenic in humans. The major
factors contributing to this immunogenicity are thought
to be the sequences of the murine C- and V-regions of an
antibody molecule [55]. Immunogenicity of therapeutic
antibodies is a significant problem and severely limits
their widespread and repeated applications to treat many
diseases. A process of antibody humanization has been
employed to structure the mouse antibodies within the
framework of the human antibody molecule, while
retaining the mouse antigen-binding complementary
determining regions [56]. Although partially humanized
antibodies have demonstrated significantly reduced
immunogenicity, the most desirable antibodies for thera-
peutic applications in humans would be fully humanized
antibodies [57]. Transgenic mice have been constructed
which have had their own immunoglobulin genes func-
tionally replaced with human immunoglobulin genes so
that they produce human antibodies upon immunization
[58-60]. Elimination of mouse antibody production was
achieved by inactivation of mouse Ig genes in the ES cells
by using gene-targeting technology to delete crucial cis-
acting sequences involved in the process of mouse Ig gene
rearrangement and expression. B cell development in
these mutant mice could be restored by the introduction
of megabase-sized YACs containing a human germline-
configuration H- and κ L-chain minilocus transgene. The
expression of fully human antibody in these transgenic
mice was predominant, at a level of several 100 µg /l of
blood [60]. This level of expression is several hundred-
fold higher than that detected in wild-type mice express-
ing the human Ig gene [60], indicating the importance of
inactivating the endogenous mouse Ig G genes in order to
enhance human antibody production by mice. More
recently, a human artificial chromosome (HAC) vector
containing the entire unarranged sequences of the human
Ig H-chain and κ L-chain was successfully introduced into
cows (TC cows) with the technology of microcell-medi-
ated chromosome transfer and nuclear transfer of bovine
fetal fibroblast cells [61]. The HAC was retained in calves
at a rate of 78–100% of cells. Human immunoglobulin
proteins were detected in the blood of new born calves at
a level of 13–258 µg/l. This report suggests that produc-
tion of a specific human polyclonal antibody could be
easily scaled up by direct immunization of TC cows. Nev-
ertheless, greater challenges remain for increasing expres-
sion levels of the human antibodies by inactivation of the
endogenous bovine Ig genes. With further improvements
to gene targeting technology in somatic cells and nuclear
transfer, immunologically deficient cattle or other large
domestic animals will be produced in order to provide a
platform for expressing various human Ig genes.
Other applications of gene targeting in domestic animals
Gene targeting in domestic animals has other potential
applications in both agriculture, and as human diseasePage 5 of 8
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geting modifications may include: (1) Myostatin gene,
which is involved in the expression of the 'double muscle'
phenotype of some breeds of cattle [62], it has been sug-
gested that knocking-out this gene would increase skeletal
muscle growth in animals [32]; (2) Growth hormone
gene, early studies of pigs transgenic for an exogenous
growth hormone gene showed an increased growth rate,
however poor control of its expression caused many dele-
terious side effects. Knock-in with extra copies of the
growth hormone gene should result in an elevated level of
growth hormone with a physiological pattern of release,
which may lead to an enhancement of the animal growth
rate without the negative effects. Gene targeting has been
extensively used in mice to create disease models for stud-
ying the pathologies of and therapies for human diseases.
However, in some disease models, knock-out mice may
exhibit the biochemical pathways of the pathology, but
often do not produce clinical symptoms [63]. Genetic
engineering of livestock through gene targeting could cre-
ate better models for human diseases due to greater simi-
larities in anatomy, physiology and organ size. For
example, the mouse model of human cystic fibrosis was
generated by disruption of the cystic fibrosis transmem-
brane conductance regulator (CFTR) gene, however, the
utility of the CFTR-knock-out mice in studying the patho-
genesis of cystic fibrosis has been limited because of their
failure, despite the presence of severe intestinal disease, to
develop lung disease [64,65] due to differences in lung
physiology. There are substantial similarities between
humans and sheep in lung physiology, anatomy, DNA
sequence of the CFTR gene, and tissue specific expression
patterns of the CFTR gene [66]. Therefore, a knock-out of
the CFTR gene in sheep could produce a better model for
human cystic fibrosis.
Conclusions
The combined technologies of gene targeting in somatic
cells and animal cloning permit the introduction of spe-
cific genetic modifications into the genome of domestic
animals. Although gene targeting in mouse ES cells has
become a routine procedure in many laboratories world-
wide, the efficiency of gene targeting in somatic cells is
still very low. For some genes, it is even impossible to
implement the strategy of gene targeting using promoter-
less targeting vectors, due to the lack of active promoters
in fibroblasts and other types of somatic cells. Neverthe-
less, continuous research efforts aimed at cloning stem
cells of domestic animals might eventually provide a plat-
form for efficient gene targeting using the technology sim-
ilar to that for mouse ES cells. The application of gene
targeting technologies in domestic animals for xenotrans-
plantation has made significant progress in recent years.
Generation of homozygous knock-out pigs for the α-1, 3-
galactosyltransferase gene will eventually elucidate the
mechanism(s), and lead to the prevention of hyper-acute
immuno-rejection of transplanted tissues and organs. In
the foreseeable future, gene targeting will likely play a
major role in the manufacture of pharmaceuticals, and
comprise much of the research examining physiological
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